奈达铂和顺铂同步放化疗治疗中晚期宫颈癌的临床疗效观察

摘要

Objective:To investigate the clinical efficacy and toxicities of nedaplatin and cisplatin concurrent chem-oradiotherapy in the treatment of advanced cervical cancer.Methods:82 patients with advanced cervical cancer were randomly divided into the 2 groups,concurrent chem-oradiotherapy with nedaplatin group( the treatment group) and concurrent chem-oradiotherapy with cisplatin group( the control group) , 41 cases in each group.Results:There was no statistial difference in the response rate and the survival rate between the 2 groups( P>0.05).The incidences of gastrointestinal reaction and renal dysfunction in the treatment group were lower than those in the control group( P<0.05 ) ,while the incidence of thrombopenia in the treatment group were higher than those in the control group( P<0.05 ).Conclusion:The similar anti-tumor efficacy was observed between nedaplatin and cisplatin in the concurrent chemoradiotherapy of advanced cervical Carcinoma, while the nedaplatin has the lower and more acceptable side-effects.%目的：探讨奈达铂和顺铂联合放疗治疗晚期宫颈癌的临床疗效和毒副反应。方法：82例晚期宫颈癌患者随机分为2组，奈达铂同步放化疗组（治疗组）和顺铂同步放化疗组（对照组），每组41例。结果：治疗组与对照组有效率、生存率比较差异均无统计学意义（P＞0.05），但治疗组胃肠道反应、肾功能损害发生率低于对照组，而治疗组的血小板减少发生率高于对照组，差异有统计学意义（ P＜0.05）。结论：治疗组和对照组有相似的疗效，不良反应可以耐受。